ReviewCells2019
Cell Fusion in Human Cancer: The Dark Matter Hypothesis.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 52 citations in OpenAlex.
- A Circulating Signature of Tumour Hybrid Cells and Immune Checkpoints Predicts Metastatic Progression in Lung Cancer.International journal of molecular sciences · 2026Article
- Cell-Cell Fusion as a Mechanism of Immune Evasion and Metastatic Progression.Advances in experimental medicine and biology · 2026Review
- The tumor microenvironment: adding pieces to the puzzle.Frontiers in immunology · 2025Review
- Cell fusion as a driver of metastasis: re-evaluating an old hypothesis in the age of cancer heterogeneity.Frontiers in immunology · 2025Review
- How Much Do You Fuse? A Comparison of Cell Fusion Assays in a Breast Cancer Model.International journal of molecular sciences · 2024Article
- Article
- Spontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells.Cancers · 2024Article
- Cell fusion between tumor cells and macrophages promotes the metastasis of OSCC patient through the activation of the chemokine signaling pathway.Cancer medicine · 2024Article
- Cell fusion upregulates PD-L1 expression for evasion from immunosurveillance.Cancer gene therapy · 2024Article
- Cell Fusion and Syncytia Formation in Cancer.Results and problems in cell differentiation · 2024Review
- Article
- Review
- Horizontal Transfer of Malignant Traits and the Involvement of Extracellular Vesicles in Metastasis.Cells · 2023Review
- Fibroblasts as Turned Agents in Cancer Progression.Cancers · 2023Review
- You complete me: tumor cell-myeloid cell nuclear fusion as a facilitator of organ-specific metastasis.Frontiers in oncology · 2023Review
- Impaired activity of the fusogenic micropeptide Myomixer causes myopathy resembling Carey-Fineman-Ziter syndrome.The Journal of clinical investigation · 2022Article
- Tumour Stem Cells in Breast Cancer.International journal of molecular sciences · 2022Review
- Keep Calm and Carry on with Extra Centrosomes.Cancers · 2022Review
- Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers.Annals of surgical oncology · 2021Article
- Cell-Cell Fusion Mediated by Viruses and HERV-Derived Fusogens in Cancer Initiation and Progression.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current strategies to determine tumor × normal (TN)-hybrid cells among human cancer cells include the detection of hematopoietic markers and other mesodermal markers on tumor cells or the presence of donor DNA in cancer samples from patients who had previously received an allogenic bone marrow transplant. By doing so, several studies have demonstrated that TN-hybrid cells could be found in human cancers. However, a prerequisite of this cell fusion search strategy is that such markers are stably expressed by TN-hybrid cells over time. However, cell fusion is a potent inducer of genomic instability, and TN-hybrid cells may lose these cell fusion markers, thereby becoming indistinguishable from nonfused tumor cells. In addition, hybrid cells can evolve from homotypic fusion events between tumor cells or from heterotypic fusion events between tumor cells and normal cells possessing similar markers, which would also be indistinguishable from nonfused tumor cells. Such indistinguishable or invisible hybrid cells will be referred to as dark matter hybrids, which cannot as yet be detected and quantified, but which contribute to tumor growth and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.